echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily, Johnson & Johnson new crown vaccine, advanced human trial, metformin has a new role

    Research and development daily, Johnson & Johnson new crown vaccine, advanced human trial, metformin has a new role

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    < br / > Bojian's latest research results: SMA patients continue to benefit from the treatment of nosinasheng sodium injection; Lilai tirzepatide head to head cardiovascular test in three stages is not inferior to trulicity; Johnson's new crown vaccine in advance of human trial; abbvie and genmab jointly develop a new generation of antibody drugs < br / > we focus on the latest development of pharmaceutical R & D, providing timely and accurate information reference for R & D personnel< br / > < br / > Bojian company recently released the latest results of nurture researchThe data showed that in infants with genetic diagnosis of SMA, early and continuous use of spinraza treatment lasted for 4.8 years, achieving an unprecedented survival rate (100%), and no patient needed permanent ventilationCompared with the natural course of the disease, the patients continued to maintain and gain progressive gains in motor function, and 96% of the patients were able to walk with assistanceOn the 10th, Pfizer announced that the third phase jade teen study of abrocitinib, an oral Jak1 inhibitor, had achieved positive top line resultsThe trial was carried out in 12 to 18-year-old patients with moderate to severe atopic dermatitisThe results showed that both doses of abrocitinib reached the main end point, and the safety and tolerance of the drug were goodOn the 10th, abbvie announced the positive data of phase IIa conceptual validation study of abbv-3373 in the treatment of adult patients with moderate and severe rheumatoid arthritisThis is the first clinical data of ADC drug in rheumatoid arthritis indications< br / > recently, GSK launched the post marketing safety monitoring study of recombinant herpes zoster vaccine, and plans to recruit 3300 subjects in China< br / > recently, Lilly announced that surpass-cvot, a phase III cardiovascular outcome trial to evaluate the investigational double effect GIP and GLP-1 receptor agonist tirzepatide (ly3298176), had been administered to the first patientThis is a head-to-head test that will evaluate the non inferiority and superiority of tirzepatide and the market leading GLP-1 receptor agonist, truccity 1.5mg< br / > Sanofi recently announced the positive results of phase III ikema clinical trial of sarclisa, a CD38 targeted antibody drug, in the treatment of relapsed and / or refractory multiple myelomaThe results showed that sarclisa + kafezomip + dexamethasone significantly reduced the risk of disease progression or death by 47% compared with kafezomip + dexamethasone, and showed a clinically significant deep remission< br / > impel neuropharma today announced the positive results of the critical phase 3 clinical trial stop301The study included 5650 patients with migraine attacks and evaluated the changes in migraine indicators reported by patients compared to the baselineThe study reached the primary clinical end point < br / > < br / > On the 11th, etibante acetate injection was declared on the market in China to treat the acute attack of hereditary angioedema in adults On October 10, Roche's application for the listing of the influenza drug mabaloxavir (English trade name: xofloza) in China was accepted by CDE < br / > on the 10th, BMS announced that FDA approved its new opdivo indication for the treatment of unresectable patients with advanced, recurrent or metastatic esophageal squamous cell carcinoma who had previously received fluorouracil and platinum drugs This is the first immunotherapy approved for the treatment of such patients < br / > on September 9, the listing application of bortezomib for injection, which imitated the four kinds of declaration, was changed to "in approval" status, once approved for production, it will be deemed to pass the conformity evaluation < br / > on May 10, the State Food and drug administration showed that the newly introduced contrast agent, iohexol injection, had entered the "in approval" status and was about to be approved for listing today, Illumina announced that the U.S FDA has granted the company the COVIDSeq test emergency use authorization (EUA), which is the first NGS based coronavirus diagnostic test authorized by the FDA for emergency use On the 10th, abbvie and genmab announced that they had signed a broad cooperation agreement to jointly develop and commercialize three new generation bispecific antibody drugs in the early stage of genmab, including epicortimab, duohexabody ® - CD37 and duobody-cd3x5t4 The two sides also reached early drug discovery cooperation in the development of new differential tumor therapies, mainly involving four new generation antibody drugs for solid tumors and blood tumors < br / > cancer vaccine developer ubivac and BMS recently reached a clinical trial cooperation to evaluate the safety, tolerance and preliminary efficacy of dpv-001, the first cancer vaccine developed by autophagy technology, combined with anti OX40 therapy bms-986178, as well as continuous anti PD-1 therapy opdivo < br / > on October 10, Tianyan pharmaceutical announced that it has reached strategic cooperation with Tianbian research laboratory, a subsidiary of Tianbian Mitsubishi pharmaceutical TRL will develop a new generation of antibody coupled drugs (ADC) for solid tumor targets by using safebody ®, an antibody precision masking technology independently developed by Tianyan pharmaceutical, and its unique cytotoxic loading technology < br / > < br / > < br / > recently, Gao Guoquan, Zhongshan Medical College, Sun Yat sen University, a team of Chinese scientists, published important research results on PNAS They analyzed the treatment data of thousands of patients with advanced colorectal cancer and found that among patients with advanced colorectal cancer carrying KRAS mutation, the total survival time of patients with colorectal cancer taking metformin was 37.8 months longer and the median progression free survival time (MPFs) was 8.1 months longer than that using other types of hypoglycemic drugs.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.